PA
NBSE

Parallel Advisors’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Parallel Advisors’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-6
Closed -$1K – 2524
2019
Q3 		$1K Buy
+6
New +$592 ﹤0.01% 2344

Other funds holding NBSE

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Parallel Advisors's NBSE Position: Q4 2019 in Review

Parallel Advisors sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q4 2019, closing a stake of 6 shares — an estimated $1K sold.

Parallel Advisors first reported a position in NBSE in Q3 2019 and held it in 1 quarter. The position peaked at $1K in Q3 2019. 22 funds tracked by Wall St. Rank hold NBSE as of Q4 2019.

  • Parallel Advisors reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Parallel Advisors sold 6 NeuBase Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $1K.
  • Parallel Advisors first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q3 2019 and held it in 1 quarter.
  • Parallel Advisors's NeuBase Therapeutics, Inc. Common Stock position peaked at $1K in Q3 2019.
  • 22 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Parallel Advisors's 13F filing for Q4 2019, filed 30 Jan 2020.